EBD Group today announced that on Monday, March 5, international
biotechnology industry leaders will descend on Milan, Italy, for
BIO-Europe Spring (March 5-7) to discuss and analyze the market, new
business approaches, scientific developments and policy trends that
will shape the biotechnology of the future.
On Monday, March 5, at the Milano Conference Center, some of the
most respected names in the industry will confront hot current issues.
Highlights of the day will include:
-- Rethinking the Biotech-Pharma Partnering Model: Will the whole
ever be worth more than the sum of its parts? A plenary
session exploring whether the current explosion of M&A deals
is sustainable and how it will impact drug development. Will
new drugs reach the marketplace sooner if smaller firms exit
the process earlier and earlier? Moderated by Roger Longman,
Managing Partner, Windhover Information, the plenary panel
will feature Robert I. Blum, President & CEO, Cytokinetics,
Inc.; Dr. Judith Hills, Corporate and Business Development,
VP, Licensing, Europe, Japan & Asia Pacific, Bristol-Myers
Squibb; Louis J. Scotti, VP, Marketing and Business
Development, Arena Pharmaceuticals, Inc.; Rob Wills, VP,
Alliance Management, Johnson & Johnson.
-- Financing Innovation - The View of Entrepreneurs and VCs. A
panel considering whether traditional VC models will remain
affordable and exploring new modes of financing biotechnology
innovation. With moderator Ian Nicholson, CEO, Chroma
Therapeutics and panelists Joel Besse, Partner, Atlas Venture;
Dr. Francesco De Rubertis, Partner Life Sciences, Index
Ventures Management; Dr. Claudio Semeraro, CEO, Z-Cube, and
Dr. Francesco Sinigaglia, CEO, BioXell.
-- The Globalizing of Biotech Dealmaking. A panel examining how
biotech entrepreneurs are leveraging the cost and regulatory
advantages that exist outside of Europe and the US, for
example what are the new types of transactions and alliances
that can enhance access to capital, technology, markets, and
drug development expertise on a global basis With moderator
Dr. Simba Gill, CEO, moksha8 and Venture Partner, Entrepreneur
in Residence, TPG Growth and panelists Hans Peter Hasler,
Senior VP, Head of International, Biogen Idec; Gardiner Smith,
Advisor, SHI Link; Dr. Greg Wiederrecht, VP, External
Scientific Affairs, Merck & Co., Inc.
-- The Combination of White and Red Biotechnologies. A discussion
of achievements and developments in the exciting new field of
"white" - or industrial biotech - expected to be a major
source of new products, and its convergence with "red" - or
medical biotech. With Martin Austin, Managing
Director,TransformRX; Francois Arcand, CEO, ERA Biotech; SA,
Camille Burel, Industrial Biotech Project Administrator,
EuropaBio; James C. Greenwood, President & CEO, Biotechnology
Industry Organization (BIO); Jack Grushcow, President,
Linnaeus Plant Sciences Inc.
Other workshops and panels featured on Monday, March 5, are:
-- Biocatalysis - Biology Catalysing Chemistry - Does It Work?
-- Licensing and Strategic Alliances: How to Get Married and
Avoid an Ugly Divorce
-- A Different Perspective on Alliances: Partnerships with
Research Tools and Service Companies as a Mechanism to Build
Value in Early Stage Biotechs
-- Biotech to Biotech Deals - How does Big Pharma look at these
Collaborations?
-- Size Isn't Everything - Can Mid-Size Pharma Compete For The
Best In-Licensing Opportunities?
-- Cancer Therapeutic Session
-- What is Next in the Antibody Space?
-- Infectious Diseases Therapeutic Session
-- CNS Therapeutic Session
-- Biotechnology in Italy 2007: A financial and strategic
Analysis
A complete list of workshops, panels and abstracts can be accessed
at: http://www.ebdgroup.com/bes/ws_panels.htm
Notes to Editors:
Entry to BIO-Europe Spring is free to the media, as is full access
to the partnering system, sessions, press conferences, workshops, and
pre-arranged partnering meetings. Visit the BIO-Europe Spring
conference website at http://www.ebdgroup.com/bes/registration.htm for
detailed information on this year's conference and online
registration. When you register online, please write into the comment
field within the registration form that you are requesting a
complimentary press registration. Please fax a copy of your press pass
to complete your complimentary media registration to fax number +49
(89) 23 88 756 - 55.
About EBD Group
EBD Group is the leading partnering firm for the global
biotechnology industry. Since 1993, firms in the life sciences have
leveraged EBD Group's partnering conferences, technology and services
to identify business opportunities and develop strategic relationships
that drive their business.
EBD Group's conferences (run in collaboration with leading
industry partners and international trade associations such as BIO and
Eucomed) include BIO-Europe, the world's largest stand-alone life
science partnering conference; BIO-Europe Spring; the investor
conference, BioEquity Europe (co-organized with BioCentury
Publications); and the convergent medical technology partnering
conference, BioDevice Partnering. EBD's novel, web-based, partnering
software system is also used at numerous third-party events around the
world. Outside of the conference format, EBD Group's consultants can
provide hands-on assistance for firms seeking to in- or out-license
products and technologies.
EBD Group has offices in San Diego, Munich and London. For more
information visit www.ebdgroup.com
